Drug use in Canadian patients with trauma after cannabis legalization.

Can J Surg

From the Department of Surgery, Western University, London, Ont. (Vogt, Parry); the Division of Emergency Medicine, Department of Medicine, Western University, London, Ont. (Pace, Ball); and the London Health Sciences Trauma Program, London, Ont. (Priestap).

Published: July 2021

AI Article Synopsis

  • In Canada, the Cannabis Act made cannabis legal on October 17, 2018, allowing people to grow, buy, and use it legally.
  • A study was done at a trauma center in Ontario to see if cannabis usage changed after it became legal by looking at patients before and after legalization.
  • The study found that the rates of cannabis use among trauma patients didn't change much before and after legalization, even though more patients were tested for drugs after it was legal.

Article Abstract

Background: The federal Cannabis Act came into force on Oct. 17, 2018, in Canada, making Canada only the second country in the world to legalize the cultivation, acquisition, possession and consumption of cannabis and its by-products. This provided a unique opportunity to evaluate the impact of this legislation on drug-related trauma.

Methods: We performed a prospective observational study on the use of cannabis and other illicit drugs in the trauma population at a lead Canadian trauma centre in London, Ontario, in the 3 months before (July 1 to Sept. 30, 2018) and 3 months after (Nov. 1, 2018, to Jan. 31, 2019) the legalization of cannabis in Canada. We defined cannabis use as a positive cannabinoid screen result at the time of assessment by the trauma team. We also screened for opioids, amphetamines and cocaine.

Results: A total of 210 patients were assessed by our trauma service between July 1 and Sept. 30, 2018, and 141 patients were assessed between Nov. 1, 2018, and Jan. 31, 2019. Motor vehicle collisions were the most common cause of trauma both before (101 [48.1%]) and after (67 [47.5%]) legalization. The mean Injury Severity Score was 17.6 (standard deviation [SD] 13.0) and 19.7 (SD 14.8), respectively. Drug screens were done in 88 patients (41.9%) assessed before legalization and 99 patients (70.2%) assessed after legalization. There was no difference in the rate of positive cannabinoid screen results before and after legalization (22 [25%] v. 22 [22%]). There was a trend toward higher rates of positive cannabinoid screen results (2/10 [20%] v. 5/8 [62%]) and positive toxicology screen results (5/10 [50%] v. 6/8 [75%]) after legalization among patients with penetrating trauma, but our sample was too small to achieve statistical significance.

Conclusion: We found no difference in the rates of positive cannabinoid screen results among patients assessed at our trauma centre in the 3 months before and the 3 months after legalization of cannabis; however, there was a trend toward an increase in the rates of positive results of toxicology screens and cannabinoid screens among those with penetrating trauma. These preliminary single-centre data showing no increased rates of cannabis use in patients with trauma after legalization are reassuring.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410467PMC
http://dx.doi.org/10.1503/cjs.000620DOI Listing

Publication Analysis

Top Keywords

positive cannabinoid
16
cannabinoid screen
16
patients assessed
12
rates positive
12
trauma
10
legalization
9
patients
8
patients trauma
8
cannabis
8
trauma centre
8

Similar Publications

Empirical data on the effect of plant density (PD) and length of the vegetative phase (DVP) on plant growth, yield, and cannabinoid concentration of medicinal cannabis (Cannabis sativa L.) are still scarce, leading to a lack of specific cultivation recommendations. We conducted two greenhouse experiments to investigate the effect of PD in the range of 12-36 plants m-2 (D-trial) and DVP in the range of 1-4 weeks (V-trial) on plant morphology, biomass growth of individual plant organs, and CBD concentration of individual inflorescence fractions.

View Article and Find Full Text PDF

Application of LC-MS/MS for the Identification of Drugs of Abuse in Driver's License Regranting Procedures.

Pharmaceuticals (Basel)

December 2024

Laboratory of Forensic Toxicology, Section of Legal Medicine, Social Security and Forensic Toxicology, Department of Biomedicine and Prevention, Faculty of Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.

Drugged driving is associated with an increased risk of road accidents worldwide. In Italy, driving under the influence (DUI) of alcohol and drugs is a reason for driving disqualification or revocation of the driving license. Drivers charged with driving under the influence of alcohol and drugs must attend a Local Medical Commission (LMC) to undergo mandatory examinations to regain the suspended license.

View Article and Find Full Text PDF

Background: Cannabinoid hyperemesis syndrome (CHS) is a syndrome of cyclic nausea and vomiting in the setting of chronic cannabis use. To date, only 11 cases of CHS in pregnancy have been reported.

Case Presentation: We describe two cases of uncontrolled vomiting in pregnancy due to CHS.

View Article and Find Full Text PDF

The relationship between cannabis use and mental health is complex, as studies often report seemingly contradictory findings regarding whether cannabis use results in more positive or negative treatment outcomes. With an increasing number of individuals using cannabis for both recreational (i.e.

View Article and Find Full Text PDF

The design of dualsteric/bitopic receptor ligands as compounds capable of simultaneously interacting with both the orthosteric and an allosteric binding site has gained importance to achieve enhanced receptor specificity and minimize off-target effects. In this work, we reported the synthesis and biological evaluation of a new series of compounds, namely, the series, obtained by chemically combining the CB1R ago-positive allosteric modulators (PAM) with the cannabinoid receptors (CBRs) orthosteric agonist . Therefore, compounds were designed as dualsteric/bitopic ligands for CB1R with the aim of obtaining stronger CB1R agonists or ago-PAMs, with improved receptor subtype selectivity and reduction of central side effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!